TRPM3

Summary

TRPM3 (transient receptor potential cation channel subfamily M member 3, HGNC:17992) is a protein-coding gene on chromosome 9q21.12-q21.13, encoding Transient receptor potential cation channel subfamily M member 3 (Q9HCF6). Constitutively active, non-selective divalent cation-conducting channel that is permeable to Ca(2+), Mn(2+), and Mg(2+), with a high permeability for Ca(2+).

The product of this gene belongs to the family of transient receptor potential (TRP) channels. TRP channels are cation-selective channels important for cellular calcium signaling and homeostasis. The protein encoded by this gene mediates calcium entry, and this entry is potentiated by calcium store depletion. Alternatively spliced transcript variants encoding different isoforms have been identified.

Source: NCBI Gene 80036 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic complex neurodevelopmental disorder (Definitive, ClinGen) — +6 more curated relationships
• GWAS associations: 28
• Clinical variants (ClinVar): 288 total — 4 likely-pathogenic
• Phenotypes (HPO): 67
• Druggable target: yes
• MANE Select transcript: NM_001366145

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17992
Approved symbol	TRPM3
Name	transient receptor potential cation channel subfamily M member 3
Location	9q21.12-q21.13
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1616, LTRPC3, GON-2
Ensembl gene	ENSG00000083067
Ensembl biotype	protein_coding
OMIM	608961
Entrez	80036

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 22 protein_coding, 3 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000354500, ENST00000357533, ENST00000358082, ENST00000360823, ENST00000361823, ENST00000377097, ENST00000377101, ENST00000377105, ENST00000377110, ENST00000377111, ENST00000396280, ENST00000396283, ENST00000396285, ENST00000396292, ENST00000408909, ENST00000437699, ENST00000677594, ENST00000677713, ENST00000704565, ENST00000704566, ENST00000704567, ENST00000704568, ENST00000704569, ENST00000704571, ENST00000704573, ENST00000704574, ENST00000704575, ENST00000704576, ENST00000707140, ENST00000715550

RefSeq mRNA: 23 — MANE Select: NM_001366145 NM_001007470, NM_001007471, NM_001366141, NM_001366142, NM_001366143, NM_001366144, NM_001366145, NM_001366146, NM_001366147, NM_001366148, NM_001366149, NM_001366150, NM_001366151, NM_001366152, NM_001366153, NM_001366154, NM_020952, NM_024971, NM_206944, NM_206945, NM_206946, NM_206947, NM_206948

CCDS: CCDS43835, CCDS65064, CCDS6634, CCDS6635, CCDS6636, CCDS6637, CCDS94418, CCDS94419, CCDS94420

Canonical transcript exons

ENST00000677713 — 26 exons

Exon	Start	End
ENSE00001413703	70625482	70625517
ENSE00001577091	70591031	70591205
ENSE00001577942	70761601	70761724
ENSE00001577943	70784105	70784279
ENSE00001578225	70620076	70620365
ENSE00001580011	70598419	70598670
ENSE00001580454	70635211	70635261
ENSE00001580884	70603342	70603470
ENSE00001582695	70553160	70553310
ENSE00001583734	70615908	70616075
ENSE00001583943	70625191	70625331
ENSE00001583972	70681506	70681578
ENSE00001584087	70549542	70549674
ENSE00001585026	70827847	70828018
ENSE00001585334	70552844	70553043
ENSE00001585769	70639060	70639194
ENSE00001587612	70610609	70610749
ENSE00001588421	70621244	70621273
ENSE00001603982	70640560	70640660
ENSE00001610430	70618867	70619095
ENSE00003527495	70843003	70843127
ENSE00003562482	70862908	70863112
ENSE00003641726	70846378	70846591
ENSE00003649958	70864432	70864511
ENSE00003904981	71121178	71121621
ENSE00003906910	70529060	70537405

Expression profiles

Bgee: expression breadth ubiquitous, 193 present calls, max score 99.00.

FANTOM5 (CAGE): breadth broad, TPM avg 5.7626 / max 764.0838, expressed in 372 samples.

FANTOM5 promoters (19 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100883	1.7925	227
100890	1.1218	196
100895	1.0316	162
100891	0.4969	172
100894	0.2952	107
100892	0.2253	115
100882	0.2047	55
100904	0.1887	53
100884	0.1367	43
100893	0.0925	55

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	99.00	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	93.35	gold quality
medial globus pallidus	UBERON:0002477	89.69	gold quality
buccal mucosa cell	CL:0002336	89.18	gold quality
globus pallidus	UBERON:0001875	88.43	gold quality
sural nerve	UBERON:0015488	88.02	gold quality
inferior olivary complex	UBERON:0002127	87.39	gold quality
lateral globus pallidus	UBERON:0002476	85.24	gold quality
cerebellar vermis	UBERON:0004720	84.69	gold quality
superior vestibular nucleus	UBERON:0007227	84.61	gold quality
substantia nigra pars compacta	UBERON:0001965	84.07	gold quality
primary visual cortex	UBERON:0002436	83.87	gold quality
medulla oblongata	UBERON:0001896	83.79	gold quality
substantia nigra pars reticulata	UBERON:0001966	83.46	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.45	gold quality
pons	UBERON:0000988	83.40	gold quality
cerebellum	UBERON:0002037	83.17	gold quality
choroid plexus epithelium	UBERON:0003911	83.11	gold quality
endothelial cell	CL:0000115	82.20	silver quality
cerebellar cortex	UBERON:0002129	82.17	gold quality
ventral tegmental area	UBERON:0002691	82.14	gold quality
cerebellar hemisphere	UBERON:0002245	82.02	gold quality
right hemisphere of cerebellum	UBERON:0014890	81.46	gold quality
postcentral gyrus	UBERON:0002581	81.29	gold quality
adult mammalian kidney	UBERON:0000082	81.06	gold quality
occipital lobe	UBERON:0002021	80.71	gold quality
cortical plate	UBERON:0005343	80.58	gold quality
nephron tubule	UBERON:0001231	80.28	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.04	gold quality
midbrain	UBERON:0001891	79.95	gold quality

Single-cell (SCXA)

Detected in 12 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	3568.47
E-GEOD-180759	yes	3479.28
E-CURD-119	yes	2359.06
E-GEOD-137537	yes	1395.93
E-MTAB-9154	yes	886.93
E-HCAD-35	yes	86.34
E-MTAB-7316	yes	22.70
E-GEOD-135922	yes	18.78
E-GEOD-131882	no	2498.97
E-MTAB-6108	no	867.68
E-GEOD-109979	no	128.63
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EGR1, PAX6

miRNA regulators (miRDB)

84 targeting TRPM3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981

Literature-anchored findings (GeneRIF, showing 40)

• The hTRPM3 gene is comprised of 24 exons and maps to chromosome 9q-21.12 and is composed of 1555 amino acids with the characteristic six-transmembrane domain of TRPs and is expressed in kidney and, at lesser levels, in brain, testis, and spinal cord (PMID:12672827)
• TRPM3 is the first ion channel activated by sphingolipids. (PMID:15550678)
• the divalent cation selectivity of TRPM3 channels is regulated by altenrative splicing (PMID:15824111)
• we give an overview of the identified TRPM3 variants and compare their functional properties–{REVIEW} (PMID:17217062)
• TRPM3 may have diverse cellular functions depending on the expression of a particular variant while TRPV4 plays a central role in epithelial homoeostasis by modulating epithelial barrier function [review] (PMID:17233610)
• TRPM3 did not reveal a otosclerosis-causing mutation (PMID:18224337)
• data suggest functional relevance of TRPM3 in contractile and proliferating phenotypes of vascular smooth muscle cells (PMID:20360246)
• Our data establish that TRPM3 channels constitute a regulated entry pathway for zinc ions in pancreatic beta-cells (PMID:20401728)
• The inhibition of TRPM1 by zinc ions is primarily due to a short stretch of seven amino acids present only in the pore region of TRPM1 but not of TRPM3. (PMID:21278253)
• Progesterone (0.01-10muM) suppressed TRPM3 activity evoked by pregnenolone sulphate. (PMID:22000496)
• Calmodulin and S100A1 protein interact with N terminus of TRPM3 channel. (PMID:22451665)
• TRPM3-ICF deletion mutation variants are regulatory channel subunits fine-tuning TRPM3 channel activity. (PMID:22961981)
• Data using recombinant proteins expressed in vascular endothelial cells suggest that SigmaR1 (sigma 1-type opioid receptor) is not involved in regulation of calcium signaling via TRPC5/TRPM3 (transient receptor potential cation channels C5/M3). (PMID:23121507)
• Pregnenolone sulfate is a powerful activator of TRPM3-mediated gene transcription, while transcription is completely inhibited by mefenamic acid in cells expressing activated TRPM3 channels. (PMID:24895737)
• Missense mutation in the cation channel, TRPM3, underlies inherited cataract and glaucoma. (PMID:25090642)
• The von Hippel-Lindau tumor suppressor (VHL) represses TRPM3 directly through miR-204 and indirectly through another miR-204 target, Caveolin 1. (PMID:25517751)
• TRPM3 channel activation changes the gene expression pattern of the cells by activating transcription of c-Jun-, ATF2-, and TCF-controlled genes. (PMID:25576487)
• The TRPM3 activity is rapidly and reversibly inhibited by activation of phosphatases. (PMID:26123194)
• TRPM3 is a phosphoinositide-dependent ion channel. (PMID:26123195)
• Activation of TRPM3 channels increases the transcriptional activation potential of c-Fos in HEK293 cells. (PMID:26493679)
• Phosphoinositols regulate TRPM3. (PMID:26517445)
• This is the first study to examine the involvement of TRPM channel gene variations on the risk of SSc incidence. Our results suggest roles of TRPM3 and TRPM5 gene variants in the susceptibility to or clinical expression of Systemic sclerosis (PMID:26546534)
• rs10780946 TRPM3 polymorphism is associated with asthma-exacerbated respiratory disease susceptibility. (PMID:26891941)
• this study shows that differential expression of TRPM3 and Ca2+ flux between NK cell subtypes may provide evidence for their role in the pathomechanism involving NK cell cytotoxicity activity in chronic fatigue syndrome/myalgic encephalomyelitis (PMID:27727448)
• Genetic experiments revealed that the basic region leucine zipper proteins c-Jun and ATF2 and the ternary complex factor Elk-1 are essential to couple TRPM3 channel stimulation with the IL-8 gene. (PMID:28982580)
• Mutations of lysine residues in calmodulin binding site 2, strongly reduced calmodulin binding and TRPM3 activity indicating the importance of this domain for TRMP3-mediated calcium signaling. (PMID:29880196)
• In the three-stage genome-wide association study in South Korean population the signal in TRPM3 showed the most robust association with thyroid nodules, and those in MIBP/NKX2-1 also demonstrated a possible association. A rs4745021 variant at TRPM3 reached the genome-wide significance threshold in the meta-analysis. (PMID:30099483)
• TRPM3 activity is impaired in Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME) patients suggesting changes in intracellular Ca2+ concentration, which may impact NK cellular functions. This investigation further helps to understand the intracellular-mediated roles in NK cells and confirm the potential role of TRPM3 ion channels in the aetiology and pathomechanism of CFS/ME. (PMID:30134818)
• The fact that TRPM3 channel stimulation activates Elk-1 connects TRPM3 with the biological functions of Elk-1, including the regulation of proliferation, differentiation, survival, transcription, and cell migration. (PMID:30552902)
• Study confirmed a significant reduction in amplitude of TRPM3 currents after pregnenolone sulfate stimulation in isolated NK cells from another cohort of CFS/ME patients compared with healthy controls. (PMID:31014226)
• Our findings suggest that TRPM3 is a locus for ID and epilepsy, and should be included in genetic panels targeting these indications. (PMID:31278393)
• activation of Gs- and Gq-coupled G-protein-coupled receptors in recombinant cells and sensory neurons inhibits TRPM3 via Gbetagamma liberation (PMID:31451581)
• Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. (PMID:31736966)
• Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients. (PMID:31796045)
• Functional expression and pharmacological modulation of TRPM3 in human sensory neurons. (PMID:31985045)
• Disease-associated mutations in the human TRPM3 render the channel overactive via two distinct mechanisms. (PMID:32343227)
• Gain of channel function and modified gating properties in TRPM3 mutants causing intellectual disability and epilepsy. (PMID:32427099)
• Machine-Learned Association of Next-Generation Sequencing-Derived Variants in Thermosensitive Ion Channels Genes with Human Thermal Pain Sensitivity Phenotypes. (PMID:32575443)
• The structural basis for an on-off switch controlling Gbetagamma-mediated inhibition of TRPM3 channels. (PMID:33122432)
• TRPM3 channel activation inhibits contraction of the isolated human ureter via CGRP released from sensory nerves. (PMID:33417951)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	trpm3	ENSDARG00000039181
mus_musculus	Trpm3	ENSMUSG00000052387
rattus_norvegicus	Trpm3	ENSRNOG00000027770
drosophila_melanogaster	Trpm	FBGN0265194
caenorhabditis_elegans		WBGENE00000425
caenorhabditis_elegans	gon-2	WBGENE00001651
caenorhabditis_elegans		WBGENE00004149
caenorhabditis_elegans		WBGENE00020972
caenorhabditis_elegans		WBGENE00021404
caenorhabditis_elegans		WBGENE00021408

Paralogs (7): TRPM5 (ENSG00000070985), TRPM7 (ENSG00000092439), TRPM6 (ENSG00000119121), TRPM4 (ENSG00000130529), TRPM1 (ENSG00000134160), TRPM2 (ENSG00000142185), TRPM8 (ENSG00000144481)

Protein

Protein identifiers

Transient receptor potential cation channel subfamily M member 3 — Q9HCF6 (reviewed: Q9HCF6)

Alternative names: Long transient receptor potential channel 3, Melastatin-2

All UniProt accessions (21): Q9HCF6, A0A7I2V4C9, A0A7I2V4E8, A0A994J4I2, A0A994J4R7, A0A994J557, A0A994J563, A0A994J743, A0A994J747, A0A994J7I1, A0AA34QVQ9, A0AAQ5BIH5, A2A3F3, A2A3F4, A2A3F7, E9PBI7, G5E9G1, H0Y3D4, H7BYP1, Q4VXD4, Q504Y1

UniProt curated annotations — full annotation on UniProt →

Function. Constitutively active, non-selective divalent cation-conducting channel that is permeable to Ca(2+), Mn(2+), and Mg(2+), with a high permeability for Ca(2+). However, can be enhanced by increasing temperature and by ligands, including the endogenous neurosteroid pregnenolone sulfate and sphingosine-1 and suppressed by intracellular Mg(2+). Implicated in a variety of cellular processes, including insulin/peptide secretion, vascular constriction and dilation, noxious heat sensing, inflammatory and spontaneous pain sensitivity. In neurons of the dorsal root ganglia, functions as thermosensitive channel for the detection of noxious heat and spontaneous pain. Suggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion. Mediates Zn(2+) uptake into the lumen of pancreatic beta cell secretory granules, thereby regulating insulin secretion. Forms heteromultimeric ion channels with TRPM1 which are permeable for Ca(2+) and Zn(2+) ions. Exists as multiple splice variants which differ significantly in their biophysical properties.

Subunit / interactions. Homotetramer. Interacts with TRPM1; the interaction results in the formation of a heteromultimeric cation channel complex that are functionally different from the homomeric channels.

Subcellular location. Cell membrane.

Tissue specificity. Expressed primarily in the kidney and, at lower levels, in brain, testis, ovary, pancreas and spinal cord. Expression in the brain and kidney was determined at protein level. In the kidney, expressed predominantly in the collecting tubular epithelium in the medulla, medullary rays, and periglomerular regions; in the brain, highest levels are found in the cerebellum, choroid plexus, the locus coeruleus, the posterior thalamus and the substantia nigra. Down-regulated in renal tumors compared to normal kidney. Expressed in the lens.

Disease relevance. Neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures (NEDFSS) [MIM:620224] An autosomal dominant disorder characterized by global developmental delay, moderate to severely impaired intellectual development, poor or absent speech, congenital hypotonia, dysmorphic facial features, exotropia, and musculoskeletal issues such as hip dysplasia, hip dislocation and scoliosis. About half of patients develop various types of seizures. The disease is caused by variants affecting the gene represented in this entry. Cataract 50 with or without glaucoma (CTRCT50) [MIM:620253] A form of cataract, an opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT50 is an autosomal dominant form characterized by early onset. Affected individuals may also exhibit high-tension glaucoma and variable anterior segment defects. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Activated by the neurosteroid pregnelonone sulfate (PregS); PregS activates the channel by shifting its current-voltage activation curve toward more negative membrane potentials and also potentiates temperature-induced activation. Activated by sphingosine. Activated by heat. Intracellular Ca(2+) inhibits TRPM3 probably via interaction with Ca(2+)/calmodulin. Intracellular Mg(2+) inhibits TRPM3 activity. Both intracellular and extracellular protons block TRPM3 through probable binding sites in the pore region. Positively regulated by phosphoinositide phosphoinositol 4,5-biphosphate (PI(4,5)P2). Strongly inhibited by activation of G(i)-coupled receptors via direct binding with G-betagamma-subunits of heterotrimeric G-proteins.

Similarity. Belongs to the transient receptor (TC 1.A.4) family. LTrpC subfamily. TRPM3 sub-subfamily.

Isoforms (11)

UniProt ID	Names	Canonical?
Q9HCF6-1	1, TRPM3f	yes
Q9HCF6-2	2, TRPM3a
Q9HCF6-3	3, TRPM3b
Q9HCF6-4	4, TRPM3d
Q9HCF6-5	5, TRPM3e
Q9HCF6-6	6, TRPM3c
Q9HCF6-7	7
Q9HCF6-8	8
Q9HCF6-10	10
Q9HCF6-11	11
Q9HCF6-12	12

RefSeq proteins (23): NP_001007471, NP_001007472, NP_001353070, NP_001353071, NP_001353072, NP_001353073, NP_001353074, NP_001353075, NP_001353076, NP_001353077, NP_001353078, NP_001353079, NP_001353080, NP_001353081, NP_001353082, NP_001353083, NP_066003, NP_079247, NP_996827, NP_996828, NP_996829, NP_996830, NP_996831 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005821	Ion_trans_dom	Domain
IPR032415	TRPM_tetra	Domain
IPR037162	TRPM_tetra_sf	Homologous_superfamily
IPR041491	TRPM_SLOG	Domain
IPR050927	TRPM	Family
IPR057366	TRPM-like	Domain

Pfam: PF00520, PF16519, PF18139, PF25508

Catalyzed reactions (Rhea), 4 shown:

• Mn(2+)(in) = Mn(2+)(out) (RHEA:28699)
• Zn(2+)(in) = Zn(2+)(out) (RHEA:29351)
• Ca(2+)(in) = Ca(2+)(out) (RHEA:29671)
• Mg(2+)(in) = Mg(2+)(out) (RHEA:29827)

UniProt features (54 total): splice variant 10, sequence variant 8, topological domain 7, region of interest 7, transmembrane region 6, compositionally biased region 4, sequence conflict 4, binding site 3, mutagenesis site 3, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9J84	ELECTRON MICROSCOPY	4.21

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCF6-F1	64.70	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 796; 1017; 1018

Mutagenesis-validated functional residues (3):

Position	Phenotype
1084	enhances ph sensitivity.
1087	enhances ph sensitivity.
1098	less sensitivity toward protons.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-3295583	TRP channels

MSigDB gene sets: 311 (showing top): GOBP_PROTEIN_HOMOTETRAMERIZATION, GOBP_TRANSITION_METAL_ION_TRANSPORT, FOXO4_01, GOBP_MONOATOMIC_CATION_TRANSPORT, IRF7_01, GATA3_01, PU1_Q6, AACTTT_UNKNOWN, GOBP_PROTEIN_HOMOOLIGOMERIZATION, ZHANG_BREAST_CANCER_PROGENITORS_UP, IK3_01, GOBP_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_PROTEIN_TETRAMERIZATION, GOBP_TRANSMEMBRANE_TRANSPORT, TGGAAA_NFAT_Q4_01

GO Biological Process (10): monoatomic cation transport (GO:0006812), calcium ion transport (GO:0006816), protein homotetramerization (GO:0051289), calcium ion transmembrane transport (GO:0070588), zinc ion transmembrane transport (GO:0071577), monoatomic cation transmembrane transport (GO:0098655), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), protein tetramerization (GO:0051262), transmembrane transport (GO:0055085)

GO Molecular Function (7): monoatomic cation channel activity (GO:0005261), calcium channel activity (GO:0005262), calmodulin binding (GO:0005516), phosphatidylinositol-4,5-bisphosphate binding (GO:0005546), G-protein beta/gamma-subunit complex binding (GO:0031683), monoatomic ion channel activity (GO:0005216), metal ion transmembrane transporter activity (GO:0046873)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Stimuli-sensing channels	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
monoatomic ion transport	2
metal ion transport	2
monoatomic cation transmembrane transport	2
transport	2
monoatomic cation transmembrane transporter activity	2
protein homooligomerization	1
protein tetramerization	1
calcium ion transport	1
zinc ion transport	1
monoatomic cation transport	1
monoatomic ion transmembrane transport	1
transmembrane transport	1
protein complex oligomerization	1
cellular process	1
monoatomic ion channel activity	1
monoatomic cation channel activity	1
calcium ion transmembrane transporter activity	1
protein binding	1
phosphatidylinositol phosphate binding	1
phosphatidylinositol bisphosphate binding	1
protein-containing complex binding	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1132 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRPM3	TRPV2	Q9Y5S1	822
TRPM3	TRPA1	O75762	813
TRPM3	TRPV1	Q8NER1	792
TRPM3	TRPV3	Q8NET8	784
TRPM3	TRPV4	Q9HBA0	784
TRPM3	PKD2	Q13563	750
TRPM3	TRPC1	P48995	716
TRPM3	TJP2	Q9UDY2	684
TRPM3	KLF9	Q13886	667
TRPM3	MCOLN1	Q9GZU1	622
TRPM3	TRPC6	Q9Y210	599
TRPM3	CALM1	P02593	568
TRPM3	PKD2L1	Q9P0L9	564
TRPM3	ANK1	P16157	563
TRPM3	S100A1	P23297	534

IntAct

22 interactions, top by confidence:

A	B	Type	Score
PHC1	CBX4	psi-mi:“MI:0914”(association)	0.790
OSM	IL6ST	psi-mi:“MI:0914”(association)	0.760
CHCHD10	CLPX	psi-mi:“MI:0914”(association)	0.640
NHLH2	AP3B1	psi-mi:“MI:0914”(association)	0.530
PRR20E	SIAH2	psi-mi:“MI:0914”(association)	0.530
H1-7		psi-mi:“MI:0914”(association)	0.350
LRP3	TMEM131L	psi-mi:“MI:0914”(association)	0.350
SENP3	POTEF	psi-mi:“MI:0914”(association)	0.350
TFPT	KRBA1	psi-mi:“MI:0914”(association)	0.350
CXCL14	DCTN6	psi-mi:“MI:0914”(association)	0.350
ZRSR2	U2SURP	psi-mi:“MI:0914”(association)	0.350
DDX54	SYNCRIP	psi-mi:“MI:0914”(association)	0.350
AKAP17A	NOS1AP	psi-mi:“MI:0914”(association)	0.350
GNLY	PRKCI	psi-mi:“MI:0914”(association)	0.350
DDX54	MYO1F	psi-mi:“MI:0914”(association)	0.350
BHLHA15	RNASEH1	psi-mi:“MI:0914”(association)	0.350
CLEC3A	MACROH2A1	psi-mi:“MI:0914”(association)	0.350
TNFRSF13B	CYBA	psi-mi:“MI:0914”(association)	0.350
DDX54	CLPX	psi-mi:“MI:0914”(association)	0.350
ESRRG	TTR	psi-mi:“MI:0914”(association)	0.350

BioGRID (30): TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS), TRPM3 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IMY7, A0JPA0, A2AP18, A8DYE2, J9SQF3, O00329, O35904, O75038, P0C1Q3, P0C588, P19687, P33402, P48736, P97557, Q02108, Q09M05, Q148L1, Q1LWG4, Q2TV84, Q2WEA5, Q3USB7, Q4ZHS0, Q502J0, Q5EBA1, Q60565, Q62688, Q69ZF7, Q6P4Q7, Q6PA06, Q7L5N7, Q7TN37, Q7Z2W7, Q7Z4N2, Q80YD1, Q8BTI9, Q8BYI6, Q8BZN2, Q8CIR4, Q8NHH9, Q8R455

Diamond homologs: A0A0R4IMY7, A7T1N0, A8DYE2, E9PTA2, J9SQF3, O94759, Q2TV84, Q2WEA5, Q5XIG0, Q7TN37, Q7Z2W7, Q7Z4N2, Q8BVU5, Q8R455, Q8R4D5, Q8TD43, Q91YD4, Q9BW91, Q9ESQ5, Q9HCF6, Q9JJH7, Q9NZQ8, S5UH55, Q09297, Q8CIR4, Q923J1, Q925B3, Q96QT4, Q9BX84, Q93971, O00418, O01991, P42527, P90648, Q54SF9, Q6B9X6, Q8MY12, Q54DK4, Q86TB3, Q91ZB0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

288 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	4
Uncertain significance	221
Likely benign	24
Benign	16

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1516729	NM_001366145.2(TRPM3):c.3428G>A (p.Arg1143Lys)	Likely pathogenic
2412979	NM_001366145.2(TRPM3):c.3431A>G (p.Tyr1144Cys)	Likely pathogenic
2580894	NM_001366145.2(TRPM3):c.3397T>C (p.Ser1133Pro)	Likely pathogenic
4077407	NM_001366145.2(TRPM3):c.1840-25_1852del	Likely pathogenic

SpliceAI

6379 predictions. Top by Δscore:

Variant	Effect	Δscore
9:70537401:CCACC:C	acceptor_gain	1.0000
9:70537402:CACC:C	acceptor_gain	1.0000
9:70537402:CACCC:C	acceptor_gain	1.0000
9:70537404:CC:C	acceptor_gain	1.0000
9:70537404:CCCT:C	acceptor_loss	1.0000
9:70537405:CC:C	acceptor_gain	1.0000
9:70537405:CCTG:C	acceptor_loss	1.0000
9:70537406:C:CC	acceptor_gain	1.0000
9:70537406:C:CG	acceptor_loss	1.0000
9:70537407:T:C	acceptor_loss	1.0000
9:70549537:CACA:C	donor_loss	1.0000
9:70549538:ACACC:A	donor_loss	1.0000
9:70549539:CACCT:C	donor_loss	1.0000
9:70549540:ACCT:A	donor_loss	1.0000
9:70549541:CCTTT:C	donor_gain	1.0000
9:70549551:G:C	donor_gain	1.0000
9:70549560:AT:A	donor_gain	1.0000
9:70549670:GAGTT:G	acceptor_gain	1.0000
9:70549671:AGTT:A	acceptor_gain	1.0000
9:70549672:GTT:G	acceptor_gain	1.0000
9:70549673:TT:T	acceptor_gain	1.0000
9:70549673:TTC:T	acceptor_loss	1.0000
9:70549674:TCTG:T	acceptor_loss	1.0000
9:70549675:C:CC	acceptor_gain	1.0000
9:70549675:C:CG	acceptor_loss	1.0000
9:70549677:G:C	acceptor_gain	1.0000
9:70552305:T:TA	donor_gain	1.0000
9:70552842:A:AC	donor_gain	1.0000
9:70552843:C:CC	donor_gain	1.0000
9:70552843:CT:C	donor_gain	1.0000

AlphaMissense

11420 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000003962 (9:70933707 T>G), RS1000007117 (9:71110524 T>C), RS1000015646 (9:70697684 T>C), RS1000020072 (9:71380843 A>G), RS1000020852 (9:70565022 C>A,T), RS1000021828 (9:71283096 C>T), RS1000022517 (9:70651845 A>C), RS1000022830 (9:70872503 G>T), RS1000029266 (9:71396737 C>A), RS1000033783 (9:70670828 C>T), RS1000035167 (9:70702121 G>A,T), RS1000036384 (9:70933462 A>T), RS1000041967 (9:70785347 T>G), RS1000046705 (9:71165102 C>A,G,T), RS1000050630 (9:70924028 C>T)

Disease associations

OMIM: gene MIM:608961 | disease phenotypes: MIM:620224, MIM:620253, MIM:253250, MIM:612292

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures	Definitive	Autosomal dominant
cataract 50 with or without glaucoma	Strong	Autosomal dominant
autosomal dominant non-syndromic intellectual disability	Supportive	Autosomal dominant
intellectual disability	Limited	Autosomal dominant
schizophrenia	Limited	Autosomal dominant
cataract-glaucoma syndrome	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (2)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
syndromic complex neurodevelopmental disorder	Definitive	AD
cataract 50 with or without glaucoma	Moderate	AD

Mondo (10): neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures (MONDO:0859365), prostate cancer (MONDO:0008315), intellectual disability (MONDO:0001071), neurodevelopmental disorder (MONDO:0700092), cataract 50 with or without glaucoma (MONDO:0859382), mulibrey nanism (MONDO:0009664), Birk-Barel syndrome (MONDO:0012856), autosomal dominant non-syndromic intellectual disability (MONDO:0015802), schizophrenia (MONDO:0005090), cataract-glaucoma syndrome (MONDO:0015567)

Orphanet (5): Familial prostate cancer (Orphanet:1331), Birk-Barel syndrome (Orphanet:166108), Autosomal dominant non-syndromic intellectual disability (Orphanet:178469), Mulibrey nanism (Orphanet:2576), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

67 total (30 of 67 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000028	Cryptorchidism
HP:0000054	Micropenis
HP:0000154	Wide mouth
HP:0000218	High palate
HP:0000262	Turricephaly
HP:0000294	Low anterior hairline
HP:0000322	Short philtrum
HP:0000324	Facial asymmetry
HP:0000337	Broad forehead
HP:0000347	Micrognathia
HP:0000414	Bulbous nose
HP:0000463	Anteverted nares
HP:0000470	Short neck
HP:0000473	Torticollis
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000501	Glaucoma
HP:0000506	Telecanthus
HP:0000508	Ptosis
HP:0000518	Cataract
HP:0000541	Retinal detachment
HP:0000577	Exotropia
HP:0000582	Upslanted palpebral fissure
HP:0000729	Autistic behavior
HP:0000750	Delayed speech and language development
HP:0000767	Pectus excavatum
HP:0000996	Facial capillary hemangioma
HP:0001182	Tapered finger
HP:0001249	Intellectual disability

GWAS associations

28 associations (top):

Study	Trait	p-value
GCST000785_8	Longevity	1.000000e-06
GCST001875_3	Pubertal anthropometrics	8.000000e-07
GCST002868_17	Response to serotonin reuptake inhibitors in major depressive disorder	4.000000e-06
GCST003219_27	Advanced age-related macular degeneration	3.000000e-08
GCST003262_570	Post bronchodilator FEV1	3.000000e-06
GCST004068_44	Venous thromboembolism adjusted for sickle cell variant rs77121243-T	3.000000e-07
GCST006069_67	Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)	9.000000e-06
GCST006387_1	Thyroid nodules	2.000000e-08
GCST007576_147	Chronotype	1.000000e-08
GCST008161_82	Waist circumference adjusted for body mass index	2.000000e-06
GCST009391_637	Metabolite levels	1.000000e-07
GCST010002_320	Refractive error	3.000000e-39
GCST010320_1	PR interval	5.000000e-11
GCST010321_15	PR interval	2.000000e-12
GCST010577_7	Crohn’s disease	5.000000e-06
GCST010796_3480	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_3481	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_3482	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_3483	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_3484	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_3485	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_3486	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_3487	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_3488	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_3489	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010988_397	Adult body size	1.000000e-11
GCST011494_46	Daytime nap	3.000000e-10
GCST012299_13	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction (3df)	9.000000e-06

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0005658	response to selective serotonin reuptake inhibitor
EFO:1001492	atrophic macular degeneration
EFO:0004314	forced expiratory volume
EFO:0007934	creatinine clearance measurement
EFO:1001436	thyroid nodule
EFO:0008328	chronotype measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0010504	inositol measurement
EFO:0004462	PR interval
EFO:0004327	electrocardiography
EFO:0007828	daytime rest measurement
EFO:0008343	sex interaction measurement

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D050336	Mulibrey Nanism	C05.116.099.343.796; C16.320.240.875
D065886	Neurodevelopmental Disorders	F03.625
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C567357	Birk-Barel Mental Retardation Dysmorphism Syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3559708 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2043144	TRPM3		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: vgic — Transient Receptor Potential channels (TRP)

Most potent curated ligand interactions (17 total), top 17:

Ligand	Action	Affinity	Parameter
isosakuranetin	Channel blocker	7.3	pIC50
primidone	Channel blocker	6.2	pIC50
CIM0216	Activation	6.1	pEC50
maprotiline	Channel blocker	5.8	pIC50
clotrimazole	Agonist	5.52	pEC50
naringenin	Channel blocker	5.2	pIC50
diclofenac	Channel blocker	5.2	pIC50
(S)-liquiritigenin	Channel blocker	5.2	pIC50
sphingosine	Agonist	4.9	pEC50
pregnenolone sulphate	Activator	4.9	pEC50
dihydrosphingosine	Agonist	4.7	pEC50
Gd3+	Antagonist	4.0	pIC50
2-APB	Antagonist	4.0	pIC50
La3+	Antagonist	4.0	pIC50
chloroform	Antagonist	3.78	pIC50
halothane	Antagonist	3.28	pIC50
Mg2+	Antagonist	2.0	pIC50

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases expression	5
methylmercuric chloride	decreases expression, increases expression	3
entinostat	decreases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Aflatoxin B1	increases methylation, decreases methylation	2
propionaldehyde	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
trichostatin A	decreases expression, increases expression	1
sodium arsenite	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	decreases expression	1
Amphotericin B	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Carbamazepine	affects expression	1
Copper	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Endosulfan	decreases expression	1
Methamphetamine	affects response to substance	1
Sarin	increases expression	1
Smoke	increases expression	1
Thimerosal	increases expression	1
Tretinoin	decreases expression	1
Zinc	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4411010	Binding	Inhibition of TRPM3 channel (unknown origin)	Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model. — ACS Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9V0	Ubigene HEK293 TRPM3 KO	Transformed cell line	Female

Clinical trials (associated diseases)

600 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia